Herpes simplex Virus 1 IgG ELISA Kit

Name: Herpes simplex Virus 1 IgG ELISA Kit
SKU: DEIA344
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

serum, plasma or cerebrospinal fluid

Species Reactivity

Human

Detection Method

iELISA

Intended Use

ELISA Herpes Simplex Virus Type 1 IgG is quantitative and qualitative test for detection of human antibodies in serum, plasma or cerebrospinal fluid against Herpes Simplex Virus (HSV). For sale in the U.S. for Research Use Only. Not for use in diagnostic procedures.

Contents of Kit

1. Break apart microtiter test strips each with 8 antigen coated single wells (altogether 96), 1 frame, the coating material is inactivated, 12
2. Standard serum (ready-to-use), Human serum in phosphate buffer with protein; negative for antiHIV-Ab, anti-HBs-Ag (Hepatitis B-Virus-surface antigen) and anti HCV-Ab; preservative: < 0.1 % sodium azide, coloring: Amaranth O. 2 × 2 ml
3. Negative control serum (ready-to-use), Human serum in phosphate buffer with protein; negative for anti HIV, anti-HBs (Hepatitis B-Virus-surface antigen) and anti-HCV; preservative: < 0.1 % sodium azide, coloring: Lissamin green V . 2 ml
4. Anti-human-IgG-conjugate (ready-to-use), Anti-human-IgG from goat (polyclonal), conjugated to alkaline phosphatase, stabilized with protein stabilization solution preservative: 0.01 % methylisothiazolone, 0.01 % bromnitrodioxane.13 ml.
5. Washing solution concentrate (sufficient for 1 litre), Sodium chloride solution with Tween 20, 30 mM Tris, preservative: < 0.1 % sodium azide. 33.3 ml
6. Dilution buffer, Phosphate buffer with protein and Tween 20; preservative: < 0.1 % sodium azide, 0.01 g/l Bromphenol blue sodium salt. 2 × 50 ml
7. Stopping solution, 1.2 N sodium hydroxide. 15 ml
8. Substrate (ready-to-use), Para-nitrophenylphosphate, solvent free buffer, preservative: < 0.1 % sodium azide. (Substrate in unopened bottle may have a slightly yellow coloring. This does not reduce the quality of the product!) 13 ml

Storage

Reagent	Storage	Stability
microtiter strips (antigen)	after opening at 2-8°C in closed aluminum bag with desiccant. Strips which are not used must be stored in the press-seal bag of aluminum compound foil under dry and airtight conditions!	4 weeks
control sera / standard sera	after opening at 2-8°C	until expiry date; 24 months from date of production
conjugate	ready-to-use solution, at 2-8°C, Avoid contamination (sterile tips!)	until expiry date 28 months from date of production
washing solution	concentrate after opening at 2-8°C; working dilution at 2-8°C; working dilution at room temperature. Bottles used for the working dilution should be cleaned regularly, discard cloudy solutions.	until expiry date; 2 weeks; 1 week
dilution buffer	after opening at 2-8°C, Discard cloudy solutions!; unopened	24 months; until expiry date; 36 months from date of production
substrate	ready-to-use solution at 2-8°C, protected from light! Avoid contamination (sterile tips!) Discard when solution turns yellow (extinction against distilled water > 0.25).	until expiry date 24 months from date of production
stopping solution	after opening at room temperature	until expiry date

General Description

Herpes Simplex Virus 1 (HSV1) and Herpes Simplex Virus 2 (HSV2) are human pathogen DNA viruses belonging to the family of Herpesviridae.
Herpes viruses are globally spread. Primary infection can be caused by contact with infected persons (saliva or urogenital secretion), cross-placentally or iatrogenically through transfusions or transplantations. After primary infection, local ganglions show lifelong virus persistence, enabling the reactivation of latent infections. The transmission of Herpes genitalis during delivery can progress subclinically. In most cases it leads to localized or disseminated sepsis-like diseases.
After primary infection, viruses persist in certain cell types (latent cycle) until reactivation (lytic cycle). Reactivation occasionally progresses without symptoms or with low pathology in immunocompetent persons whereas severe clinical complications occur in immunocompromised patients.

Citations

Have you cited DEIA344 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

Infectious Disease Test Kits and Positive Controls

QA & Reviews

Customer Reviews

References

Production of the bioactive plant-derived triterpenoid morolic acid in engineered Saccharomyces cerevisiae

BIOTECHNOLOGY AND BIOENGINEERING

Authors: Srisawat, Pisanee; Yasumoto, Shuhei; Fukushima, Ery O.; Robertlee, Jekson; Seki, Hikaru; Muranaka, Toshiya

Abstract

Morolic acid is a plant-derived triterpenoid that possesses pharmacological properties such as cytotoxicity, as well as anti-HIV, anti-HSV, anti-inflammatory, and antidiabetic effects. The significant therapeutic properties of morolic acid are desirable in the context of pharmacological and drug development research, but the low accessibility of morolic acid from natural resources limits its applications. In the present study, we developed a microbial system for the production of morolic acid. Using a combinatorial biosynthesis approach, a novel production pathway was constructed in Saccharomycescerevisiae by coexpressing BfOSC2 (germanicol synthase) from Bauhinia forficata and CYP716A49 (triterpene C-28 oxidase) from Beta vulgaris. Moreover, we reconstructed the cellular galactose regulatory network by introducing a chimeric transcriptional activator (fusion of Gal4dbd.ER.VP16) to overdrive the genes under the control of the galactose promoter. We also overexpressed truncated HMG1, encoding feedback-inhibition-resistant form of 3-hydroxy-3-methylglutaryl-coenzyme A reductase 1 and sterol-regulating transcription factor upc2-1, to increase the isoprenoid precursors in the mevalonate pathway. Using this yeast system, we achieved morolic acid production up to 20.7 +/- 1.8 mg/L in batch culture. To our knowledge, this is the highest morolic acid titer reported from a heterologous host, indicating a promising approach for obtaining rare natural triterpenoids.

HSV-1 and Zika Virus but Not SARS-CoV-2 Replicate in the Human Cornea and Are Restricted by Corneal Type III Interferon

CELL REPORTS

Authors: Miner, Jonathan J.; Platt, Derek J.; Ghaznavi, Cyrus M.; Chandra, Pallavi; Santeford, Andrea; Menos, Amber M.; Dong, Zhenyu; Wang, Erin R.; Qian, Wei; Karozichian, Elysse S.; Philips, Jennifer A.; Apte, Rajendra S.

Abstract

Here, we report our studies of immune-mediated regulation of Zika virus (ZIKV), herpes simplex virus 1 (HSV-1), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the human cornea. We find that ZIKV can be transmitted via corneal transplantation in mice. However, in human corneal explants, we report that ZIKV does not replicate efficiently and that SARS-CoV-2 does not replicate at all. Additionally, we demonstrate that type III interferon (IFN-lambda) and its receptor (IFN lambda R1) are expressed in the corneal epithelium. Treatment of human corneal explants with IFN-lambda, and treatment of mice with IFN-lambda eye drops, upregulates antiviral interferon-stimulated genes. In human corneal explants, blockade of IFN lambda R1 enhances replication of ZIKV and HSV-1 but not SARS-CoV-2. In addition to an antiviral role for IFN lambda R1 in the cornea, our results suggest that the human cornea does not support SARS-CoV-2 infection despite expression of ACE2, a SARS-CoV-2 receptor, in the human corneal epithelium.